Search Results - "ЭНДОПРОТЕЗИРОВАНИЕ СУСТАВОВ"

Source: Bolʹ, Sustavy, Pozvonočnik, Vol 9, Iss 3, Pp 184-198 (2019)
PAIN. JOINTS. SPINE; Том 9, № 3 (2019); 184-198
Боль. Суставы. Позвоночник-Bolʹ, sustavy, pozvonočnik; Том 9, № 3 (2019); 184-198
Біль. Суглоби. Хребет-Bolʹ, sustavy, pozvonočnik; Том 9, № 3 (2019); 184-198

Subject Terms: rheumatoid arthritis, infection, risk, joint replacement, Medicine (General), періопераційний менеджмент, ревматоїдний артрит, ендопротезування суглобів, інфекція, ризик, хворобомодифікуючі антиревматичні препарати, глюкокортикоїди, біологічна терапія, інгібітори фактора некрозу пухлини, glucocorticoids, tumor necrosis factor inhibitors, perioperative management, disease modifying antirheumatic drugs, biological therapy, 3. Good health, 03 medical and health sciences, периоперационный менеджмент, ревматоидный артрит, эндопротезирование суставов, инфекция, риск, болезньмодифицирующие антиревматические препараты, глюкокортикоиды, биологическая терапия, ингибиторы фактора некроза опухоли, R5-920, 0302 clinical medicine

File Description: application/pdf

Access URL: https://pjs.zaslavsky.com.ua/index.php/journal/article/download/259/278
https://doaj.org/article/9d0f70ec60c6478897090f7dbcfc3be5
https://cyberleninka.ru/article/n/perioperative-management-of-patients-with-rheumatoid-arthritis
http://pjs.zaslavsky.com.ua/article/download/178643/183174
http://pjs.zaslavsky.com.ua/article/view/178643
http://pjs.zaslavsky.com.ua/article/view/178643

View record at OpenAIRE Full Text Finder

5

Academic Journal

Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022 ; Обновленные рекомендации Американской коллегии ревматологов/Американской ассоциации хирургов тазобедренного и коленного суставов по периоперационному назначению противоревматических препаратов пациентам с ревматическими заболеваниями, которым выполняется тотальное эндопротезирование тазобедренного или коленного сустава 2022

Authors: V. N. Amirjanova, M. A. Makarov, A. E. Karateev, A. E. Khramov, S. V. Maglevaniy, A. V. Rozov, V. A. Nesterenko, E. L. Nasonov, В. Н. Амирджанова, М. А. Макаров, А. Е. Каратеев, А. Э. Храмов, С. В. Маглеваный, А. В. Розов, В. А. Нестеренко, Е. Л. Насонов

Source: Rheumatology Science and Practice; Vol 61, No 3 (2023); 260-267 ; Научно-практическая ревматология; Vol 61, No 3 (2023); 260-267 ; 1995-4492 ; 1995-4484

Subject Terms: глюкокортикоиды, joint replacement, rheumatic diseases, basic anti-inflammatory drugs, genetically engineered biological drugs, janus kinases, glucocorticoids, эндопротезирование суставов, ревматические заболевания, базисные противовоспалительные препараты, генно-инженерные биологические препараты, янус-киназы

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3353/2281; Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, van Voorhees AS, Armstrong AW, et al. From the medical board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2016;75:798-805.e7. doi:10.1016/j.jaad.2016.06.014; Лила АМ, Насонов ЕЛ, Коротаева ТВ. Псориатический артрит: патогенетические особенности и инновационные методы терапии. Научно-практическая ревматология. 2018;56(6):685-691. doi:10.14412/1995-4484-2018-685-691; Tung K, Lee Y, Lin C, Lee C, Lin M, Wei JC. Opposing trends in total knee and hip arthroplasties for patients with rheumatoid arthritis vs. the general population: A 14-year retrospective study in Taiwan. Front Med. 2021;8:502. doi:10.3389/fmed.2021.640275; Mertelsmann-Voss C, Lyman S, Pan TJ, Goodman S, Figgie MP, Mandl LA. Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991–2005. J Rheumatol. 2014;41:867-874. doi:10.3899/jrheum.130617; Nikiphorou E, Carpenter L, Morris S, Macgregor AJ, Dixey J, Kiely P, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: Results from two UK inception cohorts. Arthritis Rheumatol. 2014;66:1081-1089. doi:10.1002/art.38344; Richter MD, Crowson CS, Matteson EL, Makol A. Orthopedic surgery among patients with rheumatoid arthritis: A population-based study to identify risk factors, sex differences, and time trends. Arthritis Care Res (Hoboken). 2018;70(10):546-1550. doi:10.1002/acr.23499; Ward MM. Risk of total knee arthroplasty in young and middleaged adults with ankylosing spondylitis. Clin Rheumatol. 2018;37: 3431-3433. doi:10.1007/s10067-018-4246-4; Ravi B, Croxford R, Hollands S, Paterson JM, Bogoch E, Kreder H, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(2):254-263. doi:10.1002/art.38231; Richardson SS, Kahlenberg CA, Goodman SM, Russell LA, Sculco TP, Sculco PK, et al. Inflammatory arthritis is a risk factor for multiple complications after total hip arthroplasty: A population-based comparative study of 68,348 patients. J Arthroplasty. 2019;34:1150-1154.e2. doi:10.1016/j.arth.2019.02.018; Goodman SM, Miller AS, Turgunbaev M, Guyatt G, Yates A, Springer B, et al. Clinical practice guidelines: incorporating input from a patient panel. Arthritis Care Res (Hoboken). 2017;69:1125-1130. doi:10.1002/acr.23275; Goodman SM, Bykerk VP, DiCarlo E, Cummings RW, Donlin LT, Orange DE, et al. Flares in patients with rheumatoid arthritis after total hip and total knee arthroplasty: Rates, characteristics, and risk factors. J Rheumatol. 2018;45:604-611. doi:10.3899/jrheum.170366; Goodman SM, Mirza SZ, DiCarlo EF, Pearce-Fisher D, Zhang M, Mehta B, et al. Rheumatoid arthritis flares after total hip and total knee arthroplasty: Outcomes at one year. Arthritis Care Res (Hoboken). 2020;72:925-932. doi:10.1002/acr.24091; Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785-791. doi:10.1136/ard.2010.128637; Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-2300. doi:10.1002/art.10529; Cordtz RL, Zobbe K, Højgaard P, Kristensen LE, Overgaard S, Odgaard A, et al. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: A nationwide cohort study using Danish healthcare registers. Ann Rheum Dis. 2018;77:281. doi:10.1136/annrheumdis-2017-212339; Goodman SM, Springer BD, Chen AF, Davis M, Fernandez DR, Figgie M, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheum. 2022;74(9):1464-1473. doi:10.1002/art.42140; Михельс Х, Никишина ИП, Федоров ЕС, Салугина СО. Генноинженерная биологическая терапия ювенильного артрита. Научно-практическая ревматология. 2011;49(1):78-93. doi:10.14412/1995-4484-2011-873; Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. 2017;69:1538-1551. doi:10.1002/art.40149; Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):746-747. doi:10.2106/JBJS.9408.ebo746; Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):e278S-e325S. doi:10.1378/chest.11-2404; Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleisch mann KE, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009;120(21):e169-e276. doi:10.1161/CIRCULATIONAHA.109.192690; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2009;54(22):e13-e118. doi:10.1016/j.jacc.2009.07.010; Логинова ЕЮ, Корсакова ЮЛ, Колтакова АД, Губарь ЕЕ, Карпова ПЛ, Глухова СИ, и др. Эффективность и безопас ность апремиласта у больных псориатическим артритом в сочетании с коморбидной патологией в клинической прак тике. Научнопрактическая ревматология. 2019;57(3):299-306. doi:10.14412/1995-4484-2019-299-306; Hernigou P, Dubory A, Potage D, Roubineau F, Flouzat-Lachaniette CH. Outcome of knee revisions for osteoarthritis and inflammatory arthritis with postero-stabilized arthroplasties: A mean ten-year follow-up with 9 0 knee revisions. Int Orthop. 2017;41(4):757-763. doi:10.1007/s00264-016-3319-8; Ren Y, Yang Q, Luo T, Lin J, Jin J, Qian W, et al. Better clinical outcome of total knee arthroplasty for rheumatoid arthritis with perioperative glucocorticoids and disease-modifying antirheumatic drugs after an average of 11.4-year follow-up. J Orthop Surg Res. 2021;16(1):84. doi:10.1186/s13018-021-02232-9; Borgas Y, Gülfe A, Kindt M, Stefansdottir A. Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties. BMC Musculoskelet Disord. 2020;21(1):410. doi:10.1186/s12891-020-03459-z; George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, et al. Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty. Arthritis Care Res (Hoboken). 2017;69(12):1845-1854. doi:10.1002/acr.23209; George MD, Baker JF, Winthrop K, Alemao E, Chen L, Connolly S, et al. Timing of abatacept before elective arthroplasty and risk of postoperative outcomes. Arthritis Care Res (Hoboken). 2019;71(9):1224-1233. doi:10.1002/acr.23843; Насонов ЕЛ. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5): 539-548. doi:10.14412/1995-4484-2018-539-548; Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62-79. doi:10.14412/1995-4484-2020-62-79; Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть II). Научно-практическая ревматология. 2020;58(2):214-224. doi:10.14412/1995-4484-2020-214-224; Авдеева АС, Мисиюк АС, Сатыбалдыев АМ, Лукина ГВ, Сороцкая ВН, Жиляев ЕВ, и др. Анализ результатов терапии тофацитинибом в реальной клинической практике (по данным Общероссийского регистра больных артритом ОРЕЛ). Научно-практическая ревматология. 2020;58(3):262-267. doi:10.14412/1995-4484-2020-262-267; Kaine J, Tesser J, Takiya L, DeMasi R, Wang L, Snyder M, et al. Reestablishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis. Clin Rheumatol. 2020;39(7):2127-2137. doi:10.1007/s10067-020-04956-1; Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi:10.14412/1995-4484-2019-8-16; Насонов ЕЛ, Денисов ЛН, Станислав МИ. Новые аспекты фармакотерапии ревматоидного артрита: ингибиторы малых молекул. Научно-практическая ревматология. 2012;50(2):66-75. doi:10.14412/1995-4484-2012-1276; Насонов ЕЛ, Коротаева ТВ. Ингибиторы Янус-киназ при иммуновоспалительных заболеваниях: 10 лет клинической практики в ревматологии. Научно-практическая ревматология. 2022;60(2): 131-148. doi:10.47360/1995-4484-2022-131-148; Муханов ВВ, Рыбников АВ, Попкова ТВ, Макаров МА. Эндопротезирование тазобедренных суставов у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2020;58(2):191-197. doi:10.14412/1995-4484-2020-191-197; Насонов ЕЛ, Авдеева АС, Попкова ТВ. Новые возможности фармакотерапии системной красной волчанки: перспективы применения анифролумаба (моноклональные антитела к рецепторам интерферона типа I). Научно-практическая ревматология. 2021;59(5):537-546. doi:10.47360/1995-4484-2021-537-546; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi:10.47360/1995-4484-2021-367-383; Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi:10.1016/S0140-6736(10)61354-2; Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668. doi:10.1002/14651858.CD010668.pub2; Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089; Fein AW, Figgie CA, Dodds TR, Wright-Chisem J, Parks ML, Mandl LA, et al. Systemic lupus erythematosus does not increase risk of adverse events in the first 6 months after total knee arthroplasty. J Clin Rheumatol. 2016;22(7):355-359. doi:10.1097/RHU.0000000000000435; Merayo-Chalico J, Gónzalez-Contreras M, Ortíz-Hernández R, Alcocer-Varela J, Marcial D, Gómez-Martín D. Total hip arthroplasty outcomes: An 18-year experience in a single center: Is systemic lupus erythematosus a potential risk factor for adverse outcomes? J Arthroplasty. 2017;32(11):3462-3467. doi:10.1016/j.arth.2017.06.021; Li Z, Du Y, Xiang S, Feng B, Bian Y, Qian W, et al. Risk factors of perioperative complications and transfusion following total hip arthroplasty in systemic lupus erythematosus patients. Lupus. 2019;28(9):1134-1140. doi:10.1177/0961203319862609; Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169. doi:10.1001/jamanetworkopen.2018.4169; Chukir T, Goodman SM, Tornberg H, Do H, Thomas C, Sigmund A, et al. Perioperative glucocorticoids in patients with rheumatoid arthritis having total joint replacements: Help or harm? ACR Open Rheumatol. 2021;3(9):654-659. doi:10.1002/acr2.11306; Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316. doi:10.14412/1995-4484-2020-304-316; Насонов ЕЛ, Лила АМ. Перспективы применения упадацитиниба при ревматоидном артрите и других иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2020;58(5):532-543. doi:10.47360/1995-4484-2020-532-543; Насонов ЕЛ, Коротаева ТВ, Дубинина ТВ, Лила АМ. Ингибиторы ИЛ23/ИЛ17 при иммуновоспалительных ревматических заболеваниях: новые горизонты. Научно-практическая ревматология. 2019;57(4):400-406. doi:10.14412/1995-4484-2019-400-406; Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356. doi:10.1002/14651858.CD007356.pub2; Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview. CMAJ. 2009;181(11):787-796. doi:10.1503/cmaj.091391; Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;2009(4):CD007277. doi:10.1002/14651858.CD007277.pub2; Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al.; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-920. doi:10.1136/ard.2010.144998; Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al.; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625-2632. doi:10.1002/art.27555

Availability: https://rsp.mediar-press.net/rsp/article/view/3353
https://doi.org/10.47360/1995-4484-2023-260-267

View record from BASE

6

Academic Journal

Материалы для имплантов опорно-двигательного аппарата человека

Contributors: Кадолич, Ж. В.

Subject Terms: Конструкционные полимерные материалы, Опорно-двигательный аппарат, Эндопротезирование суставов, Эндопротезы тазобедренных суставов

File Description: application/pdf

Access URL: https://elib.gstu.by/handle/220612/26729

View record at OpenAIRE

7

Academic Journal

Позитивный опыт пролонгирования спортивной активности после эндопротезирования крупных суставов

Authors: Grishin, S.E., Fedonnikov, A.S., Andriyanova, E.A., Norkin, I.A.

Subject Terms: sports medicine, теннис, спортивная медицина, orthopedics, arthroplasty, tennis, ортопедия, реабилитация, УДК 616.728.2/3-036.868, эндопротезирование суставов, rehabilitation

File Description: application/pdf

Access URL: http://dspace.susu.ru/xmlui/handle/00001.74/46153

View record at OpenAIRE

8

Academic Journal

Влияние метода анестезии и анальгезии на формирование хронического болевого синдрома у пациентов, перенесших тотальное эндопротезирование коленного или тазобедренного сустава

Authors: Михаил Евгеньевич Политов, Н. В. Панов, А. М. Овечкин, С. В. Сокологорский

Source: Вестник интенсивной терапии, Iss 1 (2020)

Subject Terms: хронический послеоперационный болевой синдром, эндопротезирование суставов, анестезия, анальгезия, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9

File Description: electronic resource

Relation: https://intensive-care.ru/index.php/acc/article/view/3; https://doaj.org/toc/1726-9806; https://doaj.org/toc/1818-474X

Access URL: https://doaj.org/article/7380a0f9726c4be284d4727ede595e56

View record in DOAJ

9

Academic Journal

The experience of surgical treatment of tuberculosis and non-specific arthritis with two-stage arthroplasty using articulating cement spacers saturated with antibiotics ; Опыт хирургического лечения туберкулезного и неспецифического артрита методом двухэтапной артропластики с использованием артикулирующих цементных спейсеров, насыщенных антибиотиками

Authors: V. S. Zubikov, E. O. Peretsmanas, I. A. Gerasimov, В. С. Зубиков, Е. О. Перецманас, И. А. Герасимов

Source: Tuberculosis and Lung Diseases; Том 97, № 11 (2019); 25-32 ; Туберкулез и болезни легких; Том 97, № 11 (2019); 25-32 ; 2542-1506 ; 2075-1230

Subject Terms: двухэтапное эндопротезирование суставов, articulating cement spacers, methyl methacrylic cement saturated with antibiotics, two-stage joint replacement, артикулирующие цементные спейсеры, метилметакриловый цемент, насыщенный антибиотиками

File Description: application/pdf

Relation: https://www.tibl-journal.com/jour/article/view/1351/1353; Волошин В. П., Еремин А. В., Зубиков В. С., Шатохина С. Н., Мартыненко Д. В., Захарова Н. М. Ошкуков С. А. Место цитологического исследования в диагностике и мониторинге периимплантного воспаления крупных суставов // Вестн. травматол. ортопед. ‒ 2013. ‒ № 1. ‒ С. 58-62.; Волошин В. П., Еремин А. В., Оноприенко Г. А., Лекишвили М. В., Васильев М. Г. Двухэтапное тотальное замещение тазобедренных суставов в условиях глубокой перипротезной инфекции // Вестн. травматол. ортопед. ‒ 2012. ‒ № 4. ‒ С. 3-9.; Зубиков В. С., Волошин В. В., Еремин А. В., Перецманас Е. О. Способ эндопротезирования тазобедренного сустава. Патент на изобретение РФ № 2480175, зарегестрировано в ГРИ РФ 27.04.2013 г., приоритет от 22.12.2011 г.; Сердобинцев М. С., Бердес А. И., Кафтырев А. С., Советова Н. А. Хирургическое лечение осложненного течения коксита с применением артикулирующих цементных спейсеров: Мат-лы Всероссийской научно-практической конференции с международным участием, посвященной памяти проф. А. Н. Горячева «Риски и осложнения в современной травматологии и ортопедии». – Омск, 2015. – С. 162-163.; Cho Y. J., Patel D., Chun Y. S., Shin W. J., Rhyu K. H. Novel antibiotic-loaded cement femoral head spacer for the treatment of advanced pyogenic arthritis in adult hip // J. Arthroplasty. ‒ 2018 ‒ Vol. 33, № 6. ‒ Р. 1899-1903.; Huang T. W., Huang K. S., Lee P. S., Tai S. L., Hsiech P. N. Encouraging outcomes of staged, uncemented arthroplasty with short-term antibiotic therapy for treatment of recalcitrant septic arthritis of the native hip // J. Trauma. ‒ 2010. ‒ Vol. 68, № 4. ‒ Р. 965-969.; Kelm J., Bohrer P., Shmitt E., Anagnostacos K. Treatment of proximal femur infections with antibiotic-loaded sement spacer // Int. J. Med. Sci. ‒ 2009. ‒ Vol. 6, № 5. ‒ Р. 258-264.; Romano C. L., Romano D., Meani E., Logoluso N., Drago L. Two stage revision surgery with preformed spacers and cementless implants for ceptic hip arthritis: a prospective, non-randomized cohort study // BMC Infect. Dis. ‒ 2011. ‒ Vol. 16, № 11. ‒ Р. 129-136.; Shen H., Wang Q. G., Zhang X. L, Jiang Y. Novel articulating medullary-sparing spacer for the treatment of infectious hip arthritis // Orthopedics. ‒ 2013. ‒ Vol. 36, № 4. ‒ Р. 404-408.; Uchiyama K., Takahira N., Fukushima K., Moriya M., Yamamoto T., Minegishi Y., Sakai R., Itoman M., Takaso M. Two-stage revision hip replacement for periprosthetic infections using antibiotic-impregnated cement pads of various types and materials // Scientific World J. ‒ 2013. ‒ Р. 147248.; Yamamoto K., Miyagawa N., Masoaka T., Katori Y., ShisidoT., Imakiire A. Cement spacer loaded with antibiotic for infected implants of the hip joint // J. Arthroplasty. ‒ 2009. ‒ Vol. 24. ‒ Р. 83-88.; Zou J., Shi Z., Mei G., Xue J., Gu W., Li X. Two-stage operation to treat destructive midfoot tuberculosis: 14 cases experience // Clin. Orthop. Relat. Res. ‒ 2013. ‒ Vol. 471, № 7. ‒ Р. 2400-2406.

Availability: https://www.tibl-journal.com/jour/article/view/1351
https://doi.org/10.21292/2075-1230-2019-97-11-25-32

View record from BASE

10

Academic Journal

PERIPROSTHETIC FRACTURES AFTER JOINT REPLACEMENT: A UNIFIED CLASSIFICATION SYSTEM ; ПЕРИПРОТЕЗНЫЕ ПЕРЕЛОМЫ ПОСЛЕ ЭНДОПРОТЕЗИРОВАНИЯ СУСТАВОВ: ЕДИНАЯ СИСТЕМА КЛАССИФИКАЦИИ

Authors: Howard L.C., Duncan C.P.

Source: Traumatology and Orthopedics of Russia; Vol 24, No 1 (2018); 29-35 ; Травматология и ортопедия России; Vol 24, No 1 (2018); 29-35 ; 2542-0933 ; 2311-2905 ; 10.21823/2311-2905-2018-24-1

Subject Terms: joint replacement, periprosthetic fractures, classification system, эндопротезирование суставов, перипротезные переломы, классификация

File Description: application/pdf

Relation: https://journal.rniito.org/jour/article/view/937/693; https://journal.rniito.org/jour/article/view/937

Availability: https://journal.rniito.org/jour/article/view/937
https://doi.org/10.21823/2311-2905-2018-24-1-29-35

View record from BASE

11

Academic Journal

REVIEW OF THE 2017 AMERICAN COLLEGE OF RHEUMATOLOGY/AMERICAN ASSOCIATION OF HIP AND KNEE SURGEONS GUIDELINES FOR THE PERIOPERATIVE MANAGEMENT AND ANTIRHEUMATIC THERAPY OF PATIENTS WITH RHEUMATIC DISEASES BEFORE TOTAL KNEE AND HIP ARTHROPLASTY ; Обзор рекомендаций Американской коллегии ревматологов и Американской ассоциации хирургов по периоперационному ведению и антиревматической терапии пациентов с ревматическими заболеваниями перед тотальным эндопротезированием коленных и тазобедренных суставов – 2017

Authors: V. N. Amirdzhanova, A. E. Karateev, E. Yu. Pogozheva, В. Н. Амирджанова, А. Е. Каратеев, Е. Ю. Погожева

Source: Rheumatology Science and Practice; Vol 56, No 5 (2018); 549-555 ; Научно-практическая ревматология; Vol 56, No 5 (2018); 549-555 ; 1995-4492 ; 1995-4484 ; undefined

Subject Terms: глюкокортикоиды, arthroplasty, rheumatic diseases, disease-modifying antiinflammatory drugs, biological agents, glucocorticoids, эндопротезирование суставов, ревматические заболевания, ба- зисные противовоспалительные препараты, генно-инженерные биологические препараты

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2616/1750; Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheum. 2017;69(8):1538-51. doi:10.1002/art.40149; Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidencefrom randomized controlled trials. Am J Manag Care. 2008;14:234-54.; Ravi B, Croxford R, Reichmann WM, et al. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. Best Pract Res Clin Rheumatol. 2012;26:637-47. doi:10.1016/j.berh.2012.07.014; Mertelsmann-Voss C, Lyman S, Pan TJ, et al. Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991-2005. J Rheumatol. 2014;41:867-74. doi:10.3899/jrheum.130617; Mertelsmann-Voss C, Lyman S, Pan TJ, et al. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheum. 2014;66:1432-9. doi:10.1002/art.38384; Nikiphorou E, Carpenter L, Morris S, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arthritis Rheum. 2014;66:1081-9. doi:10.1002/art.38344; Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved longterm outcomes of rheumatoid arthritis. Ann Rheum Dis. 2007;66:341-4. doi:10.1136/ard.2006.057067; Ravi B, Croxford R, Hollands S, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:254-63. doi:10.1002/art.38231; Lin JA, Liao CC, Lee YJ, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646-51. doi:10.1136/annrheumdis-2012-202758; Singh JA, Inacio MC, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015;67:718-24. doi:10.1002/acr.22497; Roberts JE, Mandl LA, Su EP, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43:1498-502. doi:10.3899/jrheum.151373; Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-95 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):477-94 (In Russ.)]. doi:10.14412/1995-4484-2014-477-494; Goodman SM, Ramsden-Stein DN, Huang WT, et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol. 2014;41:1774-80. doi:10.3899/jrheum.140011; Goodman SM, Johnson B, Zhang M, et al. Patients with rheumatoid arthritis have similar excellent outcomes after total knee replacement compared with patients with osteoarthritis. J Rheumatol. 2016;43:46-53. doi:10.3899/jrheum.150525; LoVerde ZJ, Mandl LA, Johnson BK, et al. Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study. J Rheumatol. 2015;42:1123-30. doi:10.3899/jrheum.141251; Johnson BK, Goodman SM, Alexiades MM, et al. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013;40:617-23. doi:10.3899/jrheum.121171; Berbari EF, Osmon DR, Lahr B, et al. The Mayo prosthetic joint infection risk score: implication for surgical site infection reporting and risk stratification. Infect Control Hosp Epidemiol. 2012;33:774-81. doi:10.1086/666641; Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1713-20. doi:10.1002/art.24060; Goodman SM, Menon I, Christos PJ, et al. Management of perioperative tumour necrosis factor a inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and metaanalysis. Rheumatology (Oxford). 2016;55:573-82.; Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785-91.doi:10.1136/ard.2010.128637; Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300. doi:10.1002/art.10529; Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;Suppl 27:61-5. doi:10.1016/j.arth.2012.02.022; Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2011;60:22-3.; Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;Suppl 1:S3-8. doi:10.1016/j.amjmed.2008.06.010; Периоперационное ведение пациентов с ревматоидным артритом, нуждающихся в эндопротезировании крупных суставов нижних конечностей. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации «Ревматология». Москва: ГЭОТАР-Медиа; 2017. С. 360-70 [Perioperative management of patients with rheumatoid arthritis who need endoprosthetics of large joints of lower extremities. In: Nasonov EL, editor. Rossiyskie klinicheskie rekomendatsii «Revmatologiya» [Russian Clinical Recommendations «Rheumatology»]. Moscow: GEOTAR-Media; 2017. P. 360-70 (In Russ.)].; Амирджанова ВН, Макаров МА, Бялик ЕИ и др. Периоперационное ведение больных ревматоидным артритом. Научно-практическая ревматология. 2014;52(4):366-76 [Amirdzhanova VN, Makarov MA, Byalik EI, et al. Perioperative; management of patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):366-75 (In Russ.)]. doi:10.14412/1995-4484-2014-366-375; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al.; ACCF/AHA focused update on perioperative b blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2009;54:e13-118. doi:10.1016/j.jacc.2009.07.010; Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative b blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009;120:e169-276. doi:10.1161/CIRCULATIONAHA.109.192690; Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 Suppl 2:e278S-325S.; Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94:746-7. doi:10.2106/JBJS.9408.EBO746; Савенкова НА. Амирджанова ВН, Макаров СА и др. Отменять ли базисную терапию больным ревматоидным артритом перед эндопротезированием суставов? Научно-практическая ревматология. 2011;49(5):46-50 [Savenkova NA; Amirdzhanova VN, Makarov SA, et al. Should disease-modifying therapy be stopped in patients with rheumatoid arthritis before endoprosthetic joint replacement? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(5):46-50 (In Russ.)]. doi:10.14412/1995-4484-2011-1460; Strand V, Ahadieh S, French J, et al. Systematic review and metaanalysis of serious infections with tofacitinib and biologic diseasemodifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362. doi:10.1186/s13075-015-0880-2; Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258-65. doi:10.1016/S0140-6736(14)61704-9; Maxwell LJ, Zochling J, Boonen A, et al. TNF-a inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468.; Ito H, Kojima M, Nishida K, et al. Postoperative complications in patients with rheumatoid arthritis using a biological agent: a systematic review and meta-analysis. Mod Rheumatol. 2015;25:672-8. doi:10.3109/14397595.2015.1014302; Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356.; Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev. 2014;9:CD007649.; Song GG, Bae SC, Lee YH. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a metaanalysis of randomized controlled trials. Korean J Intern Med. 2014;29:656-63. doi:10.3904/kjim.2014.29.5.656; Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and longterm extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:2924-37. doi:10.1002/art.38779; Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a metaanalysis update of 44 trials. Am J Med. 2014;127:1208-32. doi:10.1016/j.amjmed.2014.06.012; Borba HH, Wiens A, de Souza TT, et al. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs 2014;28:211-28. doi:10.1007/s40259-013-0074-x; He Y, Wong AY, Chan EW, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013;14:298. doi:10.1186/1471-2474-14-298; Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD004525.; Machado MA, Barbosa MM, Almeida AM, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33:2199-213. doi:10.1007/s00296-013-2772-6; Li ZH, Zhang Y, Wang J, Shi ZJ. Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, doubleblind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013;23:497-506. doi:10.1007/s00590-012-1035-7; Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and metaanalysis informing a consensus statement. Ann Rheum Dis. 2013;72:583-9. doi:10.1136/annrheumdis-2012-202470; Lan L, Han F, Chen JH. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and metaanalysis. J Zhejiang Univ Sci B. 2012;13:731-44. doi:10.1631/jzus.B1200057; Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035- 50. doi:10.1016/j.jaad.2010.09.734; Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50:552-62. doi:10.1093/rheumatology/keq343; Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011;31:1493-9. doi:10.1007/s00296-010-1526-y; Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis. 2010;13:12-26. doi:10.1111/j.1756-185X.2009.01457.x; Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-53. doi:10.1592/phco.30.4.339; Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med. 2010;25:1-17. doi:10.3904/kjim.2010.25.1.1; An MM, Zou Z, Shen H, et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010;66:49-59. doi:10.1007/s00228-009-0754-0; Wiens A, Correr CJ, Pontarolo R, et al. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol. 2009;70:337-44. doi:10.1111/j.1365-3083.2009.02296.x; Fouque-Aubert A, Jette-Paulin L, Combescure C, et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebocontrolled trials. Ann Rheum Dis. 2010;69:1756-61. doi:10.1136/ard.2008.098822; Leombruno JP, Einarson TR, Keystone EC. The safety of antitumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136-45. doi:10.1136/ard.2008.091025; Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor a drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. doi:10.1186/1471-2474-9-52; Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-a inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883-90.; Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33:2398-408.; Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85. doi:10.1001/jama.295.19.2275; Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379-84. doi:10.1136/ard.2005.035287; Capogrosso Sansone A, Mantarro S, Tuccori M, et al. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Drug Safety. 2015;38:869-88. doi:10.1007/s40264-015-0336-2; Tarp S, Furst DE, Luta G, et al. Risk of serious adverse effects associated with different biological and targeted synthetic diseasemodifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [abstract]. Ann Rheum Dis. 2015;74 Suppl 2:176-7.; De la Forest M, Brugneaux J, Utard G, Salliot C. Safety of anti-TNFs in RA patients in real life: results from a systematic literature review and meta-analyses from biologic registers [abstract]. Ann Rheum Dis. 2015;74 Suppl 2:702. doi:10.1136/annrheumdis-2015-eular.2781; Hochberg M, Janssen K, Broglio K, et al. Comparison of abatacept and other biologic DMARDs for the treatment of rheumatoid arthritis patients: a systematic literature review and network metaanalysis [abstract]. Ann Rheum Dis. 2014;73 Suppl 2:676. doi:10.1136/annrheumdis-2014-eular.5331; Tarp S, Tarp U, Andersen LS, et al. Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel [abstract]. Arthritis Rheum. 2013;65 Suppl:S997-8.; He Y, Wong A, Chan E, et al. Safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Drug Safety. 2013;36:852-3.; Singh JA, Wells G, Christensen R, et al. Risk of cancer, serious lung infections and death with biologics: a systematic review and network meta-analysis of randomized controlled trials (RCTs) [abstract]. Ann Rheum Dis. 2013;72:A74. doi:10.1136/annrheumdis-2013-eular.276; Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. J Pharmacokinetics Pharmacodynamics. 2013;40:S93-4.; Lin T, Shamliyan T, Choi H, et al. The safety of anti-TNF biologic agents in rheumatoid arthritis: a metaanalysis of 35 RCTs [abstract]. Arthritis Rheum. 2012;64 Suppl:S1854.; Venson R, Wiens A, Correr CJ, Pontarolo R. Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis. Brazil J Pharm Sci. 2012;48:781-91. doi:10.1590/S1984-82502012000400022; Cormier H, Barnetche T, Schaeverbeke T. The risk of serious infection with and without anti-TNF therapy in rheumatoid arthritis and ankylosing spondylitis: a metaanalysis [abstract]. Arthritis Rheum. 2011;63 Suppl:S878.; Dommasch E, Troxel A, Shin D, et al. The safety of tumor necrosis factor antagonists in patients with psoriatic disease: a systematic review and metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:AB8. doi:10.1016/j.jaad.2010.09.734; Rieder S, Thompson A, Pope J. Anti-TNF therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. J Rheumatol. 2010;37:1343.; Powers J, Martin R. Incidence of serious infectious events with methotrexate treatment: metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2010;62:AB4.; Volkmann ER, Agrawal H, Maranian P, Furst DE. Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med. 2010;2:749-60.; Kaine JL. Abatacept for the treatment of rheumatoid arthritis: a review. Curr Ther Res. 2007;68:379-99. doi:10.1016/j.curtheres. 2007.12.001; Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34 Suppl 1:12-8. doi:10.1016/j.semarthrit.2005.01.004; Jinesh S. Pharmaceutical aspects of anti-inflammatory TNFblocking drugs. Inflammopharmacology. 2015;23:71-7. doi:10.1007/s10787-015-0229-0; Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human antitumor necrosis factor-a monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700-21. doi:10.1016/S0149-2918(03)80164-9; Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47:1119-28. doi:10.1177/0091270007305297; Погожева ЕЮ, Амирджанова ВН, Макаров СА, Насонов ЕЛ. Осложнения после эндопротезирования суставов у пациентов, получающих генно-нженерные биологические препараты. Научно-практическая ревматология. 2012;50(3):43-8 [Pogozheva EYu, Amirdzhanova VN, Makarov SA, Nasonov EL. Complications after endoprosthetic joint replacement in patients receiving genetically engineered biological agents. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(3):43-8 (In Russ.)]. doi:10.14412/1995-4484-2012-708; Tarp S, Furst DE, Maarten B, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017;56:417-25.; Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767-76. doi:10.1177/0961203309106174; Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol. 2010;29:707-16. doi:10.1007/s10067-010-1387-5; Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-30. doi:10.1002/art.30613; Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheum. 2012;64(10 Suppl):S726.; Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signaling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311-6. doi:10.1136/annrheumdis-2014-206028; Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg. 2008;143:1222-6. doi:10.1001/archsurg.143.12.1222; Harpaz R, Ortega-Sanchez I, Seward J. Prevention of herpes zoster: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30.; Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7:119-24. doi:10.2174/1874312920131210005

Availability: https://rsp.mediar-press.net/rsp/article/view/2616
https://doi.org/10.14412/1995-4484-2018-549-555

View record from BASE

12

Academic Journal

Features of diagnostic methods, surgical treatment and new rehabilitation methods of large joint total arthroplasty in patients with sarcopenia ; Особенности диагностики, хирургического лечения и новые методы реабилитации при тотальном эндопротезировании крупных суставов у пациентов с саркопенией

Authors: I. L. Filonov, A. V. Alabut, V. D. Sikilinda, D. S. Chuiko, И. Л. Филонов, А. В. Алабут, В. Д. Сикилинда, Д. С. Чуйко

Source: Medical Herald of the South of Russia; Том 9, № 2 (2018); 6-14 ; Медицинский вестник Юга России; Том 9, № 2 (2018); 6-14 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2018-9-2

Subject Terms: обзор, arthroplasty of joints, high intensity magnetic stimulation, HIMS, review, эндопротезирование суставов, высокоинтенсивная магнитная стимуляция, ВМС

File Description: application/pdf

Relation: https://www.medicalherald.ru/jour/article/view/648/452; Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., Boirie Y., Cederholm T., Landi .F, et al. Sarcopenia: European consensus on defi nition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. // Age and Ageing. – 2010. – V.39(4). – P.412-423. doi:10.1093/ageing/afq034; Kim S.H., Kim T.H., Hwang H.J. Th e relationship of physical activity (PA) and walking with sarcopenia in Korean males aged 60 years and older using the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV-2, 3), 2008-2009. // Arch Gerontol Geriatr. – 2013. – V.56(3). – P. 472–477. doi:10.1016/j.archger.2012.12.009; Ji H.M., Han J., Jin D.S., Suh H., Chung Y.S., Won Y.Y. Sarcopenia and Sarcopenic Obesity in Patients Undergoing Orthopedic Surgery. // Clin Orthop Surg. – 2016. – V.8(2). – P.194-202. doi:10.4055/cios.2016.8.2.194; Patel H.P., Syddall H.E., Jameson K., Robinson S., Denison H., Roberts H.S., et al. Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) defi nition: fi ndings from the Hertfordshire Cohort Study (HCS). // Ageand Ageing. – 2013. – V.42(3). – P.378-384. doi:10.1093/ageing/afs197; Patel H.P., White M.C., Westbury L., Syddall H.E., Stephens P.J., Clough G.F., et al. Skeletal muscle morphology in sarcopenia defi ned using the EWGSOP criteria: fi ndings from the Hertfordshire Sarcopenia Study (HSS). // BMC Geriatrics. – 2015. – V.15. – P.171. doi:10.1186/s12877-015-0171-4.; Baumgartner R.N., Waters D.L. Sarcopenia and sarcopenic obesity. Pathy MSJ, editor. Principles and Practice of Geriatric Medicine. - London, UK: John Wiley and Sons; 2006.; Lang T., Steeper T., Cawthon P., Baldwin K., Taafe D.R., Harris T.B. Sarcopenia: etiology, clinical consequences, intervention and assessment. // Osteoporosis International. – 2010. – V.21. – P.543–559. doi:10.1007/s00198-009-1059-y; Sirola J., Rikkonen T., Kröger H., Honkanen R., Tuppurainen M., Airaksinen O., et al. Factors related to postmenopausal muscle performance: a cross-sectional population-based study. // European Journal of Applied Physiology. – 2004. – V.93(1-2). – P.102–107. doi:10.1007/s00421-004-1173-7; Snih S.A., Markides K.S., Ottenbacher K.J., Raji M.A. Hand grip strength and incident ADL disability in elderlyMexican Americans over a seven-year period. // Aging Clinicaland Experimental Research. – 2004. – V.16(6). – P.481–486. doi:10.1007/BF03327406; Rantanen T., Volpato S., Ferrucci L., Heikkinen E., Fried L.P., Guralnik J.M. Handgrip strength and cause-specifi cand total mortality in older disabled women: exploring themechanism. // Journal of the American Geriatrics Society. – 2003. – V.51(5). – P.636–641.; Brown M., Sinacore D.R., Binder E.F., Kohrt W.M. Physical and performance measures for the identifi cation of mild to moderate frailty. // Journals of Gerontology Series A. – 2000. – V.55(6). – P.M350–M355.; Callahan D., Phillips E., Carabello R., Frontera W.R., Fielding R.A. Assessment of lower extremity muscle power in functionally-limited elders. // Aging Clinical and ExperimentalResearch. – 2007. – V.19(3). – P.194–199.; Newman A.B., Haggerty C.L., Goodpaster B., Harris T., Kritchevsky S., Nevitt M., et al. Strength and muscle quality in a well-functioning cohort of older adults. Th e Health, Aging and Body Composition Study. // Journal of the American Geriatrics Society. – 2003. – V.51(3). – P.323–330.; Studenski S.A., Peters K.W., Alley D.E., Cawthon P.M., McLean R.R., Harris T.B., et al. Th e FNIH sarcopenia project: rationale, study description, conference recommendations, and fi nal estimates. // J Gerontol Ser A Biol Med Sci. – 2014. – V.69(5). – P. 547–558. doi:10.1093/gerona/glu010; Chen L.K., Liu L.K., Woo J., Assantachai P., Auyeung T.W., Bahyah K.S., et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. // J Am Med Dir Assoc. – 2014. – V.15(2). – P.95–101. doi:10.1016/j.jamda.2013.11.025; Guralnik J.M., Simonsick E.M., Ferrucci L., Glynn R.J., Berkman L.F., Blazer D.G., et al. A short physical performance battery assessing lower extremity function: association with selfreported disability and prediction of mortality and nursing home admission. // Journals of Gerontology. – 1994. – V.49(2). – P. M85–M94.; Working Group on Functional Outcome Measures for Clinical Trials. Functional outcomes for clinical trials in frail older persons: time to be moving. // Journals of Gerontology Series A. – 2008. – V.63(2). – P.160–164.; Поворознюк В.В., Дзерович Н.И. Саркопения и Возраст: обзор литературы и результаты собственных исследований // Боль. Суставы. Позвоночник.- 2012. - №3(7). - С.713; Deschenes M.R. Eff ects of aging on muscle fi bre type and size. // Sports Med. – 2004. – V.34(12). – P.809–824.; Roberts H.C., Denison H.J., Martin H.J., Patel H.P., Syddall H., Cooper C., et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardized approach. // Age Ageing. – 2011. – V.40(4). – P.423–429. doi:10.1093/ageing/afr051; Patel H.P., Syddall H.E., Martin H.J., Stewart C.E., Cooper C., Sayer A.A. Hertfordshire sarcopenia study: design and methods. // BMC Geriatrics. – 2010. – V.10. – P. 43. doi:10.1186/1471-2318-10-43; Patel H.P., Syddall H.E., Martin H.J., Cooper C., Stewart C., Sayer A.A. Th e feasibility and acceptability of muscle biopsy in epidemiological studies: fi ndings from the Hertfordshire Sarcopenia Study (HSS). // J Nutr Health Aging. – 2011. – V.15(1). – P.10–15.; Janssen I., Baumgartner R.N., Ross R., Rosenberg I.H., Roubenoff R. Skeletal muscle cut points associated with elevated physical disability risk in older men and women. // Am J Epidemiol. – 2004. – V.159(4). – P. 413–421.; Song M.Y., Ruts E., Kim J., Janumala I., Heymsfi eld S., Gallagher D. Sarcopenia and increased adipose tissue infi ltration of muscle in elderly African American women. // Am J ClinNutr. – 2004. – V.79(5). – P.874–880. doi:10.1093/ ajcn/79.5.874; Reeves N.D., Maganaris C.N., Narici M.V. Ultrasonographic assessment of human skeletal muscle size. // Eur J Appl Physiol. – 2004. – V.91(1). – P.116–118. doi:10.1007/s00421003-0961-9; Narici M., Cerretelli P. Changes in human muscle architecture in disuse-atrophy evaluated by ultrasound imaging. // J Gravit Physiol. – 1998. – V.5(1). – P.73–74.; Visser M., Goodpaster B.H., Kritchevsky S.B., Newman A.B., Nevitt M., Rubin S.M., et al. Muscle mass, muscle strength, and muscle fat infi ltration as predictors of incident mobility limitations in well-functioning older persons. // J Gerontol A Biol Sci Med Sci. – 2005. – V.60(3). – P.324–333.; Bonnick S.L., Lewis L.A. Bone densitometry for technologists. - New Jersey, Totowa, Humana Press Inc., 2006.; Kim J., Heshka S., Gallagher D., Kotler D.P., Mayer L., Albu J., et al. Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy Xray absorptiometry in adults. // J Appl Physiol. – 2004. – V.97(2). – P.655–660. doi:10.1152/japplphysiol.00260.2004; Chen Z., Wang Z., Lohman T., Heymsfi eld S.B., Outwater E., Nicholas J.S., et al. Dual-energy X-ray absorptiometry is a valid tool for assessing skeletal muscle mass in older women. // J Nutr. – 2007. – V.137(12). – P.2775–2780. doi:10.1093/ jn/137.12.2775; Ундрицов В.М., Ундрицов И.М., Серова Л.Д., Саркопения – новая медицинская нозология. // Физкультура в профилактике, лечении и реабилитации. – 2009. - №4(31). С. 7-16.; Janssen I., Heymsfi eld S.B., Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. // J Am Geriatr Soc. – 2002. – V.50(5). – P.889–896.; Muscaritoli M., Anker S.D., Argilés J., Aversa Z., Bauer J.M., Biolo G., et al. Consensus defi nition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) «cachexia-anorexia in chronic wasting diseases» and «nutrition in geriatrics». // Clin. Nutr. – 2010. – V.29(2). – P. 154–159. doi:10.1016/j.clnu.2009.12.004; Buehring B., Krueger D., Binkley N. Eff ect of including historical height and radius BMD measurement on sarco-osteoporosis prevalence. // Journal of Cachexia, Sarcopenia and Muscle. – 2013. – V.4(1). – P.47-54. doi:10.1007/s13539-0120080-8; Белая Ж.Е. Саркопения: современные подходы к диагностике и лечению //Эффективная фармакотерапия. Эндокринология. –2014. - №5(46). -С. 42-49.; Shepherd J.A., Lu Y., Wilson K., Fuerst T., Genant H., et al. Cross-calibration and minimum precision standards for dual-energy X-ray absorptiometry: the 2005 ISCD Offi cial Positions. // J Clin Densitom. – 2006. – V.9(1). – P. 31-6. doi:10.1016/j.jocd.2006.05.005; Chang M.J., Kang Y.G., Chang C.B., Seong S.C., Kim T.K. Th e patterns of limb length, height, weight and body mass index changes aft er total knee arthroplasty. // J Arthroplasty. – 2013. – V.28(10). – P. 1856-1861. doi:10.1016/j.arth.2013.03.024; Lee Y.K., Ha Y.C., Yoon B.H., Koo K.H. Incidence of second hip fracture and compliant use of bisphosphonate. // Osteoporos Int. – 2013. – V.24(7). – P. 2099-2104. doi:10.1007/s00198-012-2250-0; Kang B.J., Ha Y.C., Hwang S.C., Lee Y.K., Koo K.H. Midterm results of large diameter Biolox forte ceramic head on delta ceramic liner articulation in total hip arthroplasty. // J Arthroplasty. – 2014. – V.29(12). – P. 2412-2414. doi:10.1016/j.arth.2014.03.003; Rolland Y., Lauwers-Cances V., Cristini C., Abellan van Kan G., Janssen I., Morley J.E., et al. Diffi culties with physical function associated with obesity, sarcopenia, and sarcopenicobesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l’OSteoporose) Study. // Am J ClinNutr. – 2009. – V.89(6). – P.1895-1900. doi:10.3945/ajcn.2008.26950; Insall J.N., Hood R.W., Flawn L.B., Sullivan D.J. Th e total condylar knee prosthesis in gonarthrosis: a fi ve to nine-year follow-up of the fi rst one hundred consecutive replacements. // JBone Joint SurgAm. – 1983. – V.65. – P.619-628.; Bistolfi A., Bettoni E., Aprato A., Milani P., Berchialla P., Berchialla P., et al. Th e presence and infl uence of mild depressive symptoms on post-operative pain perception following primary total knee arthroplasty. // Knee Surg Sports Traumatol Arthrosc. – 2017. – V.25(9). – P.2792-2800. doi:10.1007/s00167-015-3737-y; Błaszczak E., Franek A., Taradaj J., Widuchowski J., Klimczak J. Assessment of the effi cacy and safety of low frequency, low intensity magnetic fi elds in patients aft er knee endoprosthesisplasty. Part 1: in vitro safety. // Bioelectromagnetics. – 2009. – V.30. – P. 159-162. doi:10.1002/ bem.20457; Adravanti P., Nicoletti S., Setti S., Ampollini A., De Girolamo L. Eff ect of pulsed electromagnetic fi eld therapy in patients undergoing total knee arthroplasty: a randomised controlled trial. // International Orthopaedics. – 2014. – V. 38. – P. 397403. doi:10.1007/s00264-013-2216-7; Moretti B., Notarnicola A., Moretti L., Setti S., De Terlizzi F., et al. I-ONE therapy in patients undergoing total knee arthroplasty: a prospective, randomised and controlled study. // BMC Musculo skelet Disord. – 2010. – V.13. – P.88. doi:10.1186/1471-2474-13-88; Beswick A.D., Wylde V., Gooberman-Hill R., Blom A., Dieppe P. What proportion of patients report long-term pain aft er total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. // BMJOpen. – 2012. – V.2. – P.e000435. doi:10.1136/ bmjopen-2011-000435.; Ibrahim M.S., Khan M.A., Nizam I., Haddad F.S. Perioperative interventions producing better functional outcomes and enhanced recovery following total hip and knee arthroplasty: an evidence-based review. // BMC Med. – 2013. – V.11.- P. 37. doi:10.1186/1741-7015-11-37.; Mizner R.L., Petterson S.C., Stevens J.E., Axe M.J., SnyderMackler L. Preoperative quadriceps strength predicts functional ability one year aft er total knee arthroplasty. // JR heumatol. – 2005. – V.32. – P.1533-1539.; Bade M.J., Kohrt W.M., Stevens-Lapsley J.E. Outcomes before and aft er total knee arthroplasty compared to healthy adults. // J Orthop Sports Phys Th er. – 2010. – V.40. – P.559– 567. doi:10.2519/jospt.2010.3317; Huang C.H., Cheng C.K., Lee Y.T., Lee K.S. Muscle strength aft er successful total knee replacement: a 6- to 13-year followup. // Clin Orthop Relat Res. – 1996. – V.328. – P.147–154.; Connelly D.M., Vandervoort A.A. Eff ects of detraining on knee extensor strength and functional mobility in a group of elderly women. // J Orthop Sports Phys Th er. – 1997. – V.26. – P. 340–346.; Moxley Scarborough D., Krebs D.E., Harris B.A. Quadriceps muscle strength and dynamic stability in elderly persons. // Gait Posture. – 1999. – V.10. – P.10–20.; Mizner R.L., Petterson S.C., Snyder-Mackler L. Quadriceps strength and the time course of functional recovery aft er total knee arthroplasty. // J Orthop Sports Phys Th er. – 2005. – V.35. – P.424–436. DOI:10.2519/jospt.2005.35.7.424; Sisk T.D., Stralka S.W., Deering M.B., Griffi n J.W. Eff ect of electrical stimulation on quadriceps strength aft er reconstructive surgery of the anterior cruciate ligament. // Am J Sports Med. – 1987. –V.15. – P.215–220.; Snyder-Mackler L., De Luca P.F., Williams P.R., Eastlack M.E., Bartolozzi A.R. 3rd, et al. Refl ex inhibition of the quadriceps femoris muscle aft er injury or reconstruction of the anterior cruciate ligament. // J Bone Joint Surg Am. – 1994. – V.76(4). – P.555–560.; Snyder-Mackler L., Delitto A., Bailey S.L., Stralka S.W. Strength of the quadriceps femoris muscle and functional recovery aft er reconstruction of the anterior cruciate ligament. A prospective, randomized clinical trial of electrical stimulation. // J Bone Joint Surg Am. – 1995. – V.77(8). – P.1166–1173.; Stevens J.E., Mizner R.L., Snyder-Mackler L. Neuromuscular electrical stimulation for quadriceps muscle strengthening after bilateral total knee arthroplasty: a case series. // J Orthop Sports PhysTh er. – 2004. – V.34(1). – P.21–29. doi:10.2519/ jospt.2004.34.1.21; https://www.medicalherald.ru/jour/article/view/648

Availability: https://www.medicalherald.ru/jour/article/view/648
https://doi.org/10.21886/2219-8075-2018-9-2-6-14

View record from BASE

13

Academic Journal